Helix: Phase III readout, FDA fast track, and CRISPR liver therapy — May 2026
CRISPR-Based LDL Therapy Hits Primary Endpoint in Phase III — Single Dose Reduces LDL 70%
A single-dose CRISPR therapy reducing LDL by 70% with a 48-month durability curve rewrites the cardiovascular treatment standard. This is the data that makes gene editing a mainstream clinical modality.
→ Endpoints NewsFDA Grants Accelerated Approval to First AI-Designed Antibody for Rare Autoimmune Disease
The first FDA approval for an AI-designed antibody is not just a clinical milestone — it validates the AI drug discovery pipeline and compresses the timeline for every program behind it.
→ FDA.govStat News Investigation: GLP-1 Prescriptions Reach 1 in 12 US Adults — Supply Chain Holding
GLP-1 penetration at this scale is a structural demand signal, not a trend. The supply chain stress test and the downstream effects on cardiovascular, renal, and surgical volumes are the second-order story.
→ Stat NewsWant this every morning,
tailored to your sources?
Lumis synthesizes Hacker News, arXiv, The Batch, Latent Space — and any RSS feed you choose — into three sharp items before your day starts.
No spam. Invite when your slot opens.